Medical Condition News

RSS

ElectroCore selected as finalist in ‘Technology’ category at FT ArcelorMittal Boldness in Business awards

At the annual FT ArcelorMittal Boldness in Business awards held in London last week electroCore was one of six finalists in the ‘Technology’ category, in a competition that included over 250 companies, which Open Garden won for its FireChat digital app.

31 Mar 2015

New drug shows potential against rare type of acute leukemia

Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well.

30 Mar 2015

COPD patients receiving home oxygen have higher risk of burn injury

Researchers from the University of Texas Medical Branch at Galveston have found that patients with chronic obstructive pulmonary disease receiving home oxygen have a higher risk of burn injury. This study was published on March 30 in Mayo Clinic Proceedings.

30 Mar 2015

Blueberries may be effective in treatment for PTSD

Up to 8 percent of people in the U.S. suffer from post-traumatic stress disorder (PTSD) as the result of witnessing or being the victim of a traumatic event. People with PTSD have been in a situation in which they were at risk of death, serious injury or sexual violence or have seen first-hand loved ones faces such threats. They may experience flashbacks, emotional detachment and jumpiness, among other symptoms that affect their ability to function in everyday life.

30 Mar 2015

Patient with severe Alzheimer's shows promising benefits during treatment with Bryostatin drug

Researchers at the Blanchette Rockefeller Neurosciences Institute and the Marshall University Joan C. Edwards School of Medicine announced their findings from a new study entitled, "PSEN1 Variant in a Family with Atypical AD." An Alzheimer patient with very severe disease, genetically confirmed to have a known variant of PSEN1, showed promising benefits during treatment with the drug Bryostatin 1.

30 Mar 2015

Study finds link between neurodegenerative disorders and inflammation

Researchers from McMaster University and the Icahn School of Medicine at Mount Sinai, New York have discovered that a protein associated with neurodegenerative diseases like ALS also plays an important role in the body's natural antiviral response.

30 Mar 2015

Workplace wellness programs can help people lose weight

A new study shows that workplace wellness programs can be effective in helping people lose weight by providing healthier food choices and increasing opportunities for physical activity, particularly if these efforts are designed with the input and active participation of employees.

30 Mar 2015

CNIO researchers describe presence of MDH2 gene mutations in hereditary neuroendocrine tumors

Researchers in the Hereditary Endocrine Cancer Group of the Spanish National Cancer Research Centre -- led by Alberto Cascón and Mercedes Robledo -- have described the presence of mutations in the MDH2 gene, in a family with very rare neuroendocrine tumours associated with a high hereditary component: pheochromocytomas and paragangliomas that affect the suprarenal and parathyroid glands (groups of chromaffin cells in the central nervous system), respectively.

30 Mar 2015

Merck Serono, Intrexon partner to develop and commercialize CAR-T cancer therapies

Merck Serono, the biopharmaceutical business of Merck, and Intrexon Corporation, today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies.

30 Mar 2015

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira, Inc., a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, announces the availability of INFLECTRA (infliximab) in Canada, the country's first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy.

30 Mar 2015

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy.

30 Mar 2015

New faculty members join UNC Lineberger to help launch immunotherapy clinical trials

Two new faculty members have joined the UNC Lineberger Comprehensive Cancer Center to help launch groundbreaking immunotherapy clinical trials testing an experimental treatment in which patients' own immune cells are genetically engineered to fight their cancer.

30 Mar 2015

CRT, BioInvent, and University of Southampton partner to develop new immunotherapy treatments for cancer

Cancer Research Technology, the commercialization and development arm of Cancer Research UK and BioInvent International today announce the start of a two-year research collaboration with leading antibody researchers at the University of Southampton.

30 Mar 2015

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Phase II/III psoriasis trial for the Company's drug candidate CF101 did not achieve its primary endpoint.

30 Mar 2015

DURECT initiates DUR-928 multi-dose Phase 1 clinical trial for NAFLD, NASH and AKI

DURECT Corporation today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program.

30 Mar 2015

Healthcare reform changes boost glucose testing in states with healthcare exchanges

A new study published in a major diabetes journal suggests that healthcare reform changes have boosted glucose testing in states that formed healthcare exchanges. The result confirms Kalorama Information's predictions on the topic.

From Quest Diagnostics 30 Mar 2015

$Two surgical methods safe, effective for healing distal femur fractures$

Two surgical methods safe, effective for healing distal femur fractures

A team of orthopedic surgeons from the Perelman School of Medicine at the University of Pennsylvania has found that modern technology for healing distal femur fractures is as safe and effective as its more established alternative, without a potential shortfall of the older approach.

30 Mar 2015

Synageva announces submission of Kanuma application to Cofepris for treatment of LAL Deficiency

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare disorders, announced today the submission to the Comisión Federal para la Protección contra Riesgos Sanitarios in Mexico for Kanuma as a treatment for patients with lysosomal acid lipase deficiency (LAL Deficiency), a rare genetic disease with significant morbidity and early mortality.

30 Mar 2015

Clonidine Topical Gel fails to meet primary endpoint in Phase 3 study for treatment of painful diabetic neuropathy

BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared to placebo for the treatment of painful diabetic neuropathy did not meet statistical significance, although certain secondary endpoints showed statistically significant improvement over placebo. In addition, a strong safety profile for the product was observed.

30 Mar 2015

Medunik announces availability of PHEBURANE drug in Canada for chronic management of UCD

Medunik Canada, a Canadian pharmaceutical company specialized in rare diseases, is pleased to announce that PHEBURANE (a tasteless oral formulation of sodium phenylbutyrate), is now available for distribution in Canada. PHEBURANE is the first drug to be approved in Canada for the chronic management of urea cycle disorders (UCD) after receiving market authorisation on January 27th, 2015.

30 Mar 2015

Medical Condition News

ElectroCore selected as finalist in ‘Technology’ category at FT ArcelorMittal Boldness in Business awards

New drug shows potential against rare type of acute leukemia

COPD patients receiving home oxygen have higher risk of burn injury

Blueberries may be effective in treatment for PTSD

Patient with severe Alzheimer's shows promising benefits during treatment with Bryostatin drug

Study finds link between neurodegenerative disorders and inflammation

Workplace wellness programs can help people lose weight

CNIO researchers describe presence of MDH2 gene mutations in hereditary neuroendocrine tumors

Merck Serono, Intrexon partner to develop and commercialize CAR-T cancer therapies

Hospira announces availability of INFLECTRA (infliximab) in Canada

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

New faculty members join UNC Lineberger to help launch immunotherapy clinical trials

CRT, BioInvent, and University of Southampton partner to develop new immunotherapy treatments for cancer

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

DURECT initiates DUR-928 multi-dose Phase 1 clinical trial for NAFLD, NASH and AKI

Healthcare reform changes boost glucose testing in states with healthcare exchanges

Two surgical methods safe, effective for healing distal femur fractures

Synageva announces submission of Kanuma application to Cofepris for treatment of LAL Deficiency

Clonidine Topical Gel fails to meet primary endpoint in Phase 3 study for treatment of painful diabetic neuropathy

Medunik announces availability of PHEBURANE drug in Canada for chronic management of UCD

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Latest News